ReviewDiagnostics (Basel, Switzerland)2022
Role of Endomyocardial Biopsy in Diagnostics of Myocarditis.
Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- MicroRNAs as diagnostic and prognostic biomarkers for viral myocarditis: A systematic review and meta-analysis.International journal of cardiology. Heart & vasculature · 2026Article
- Unmasking Cardiac Sarcoidosis: Integrating Multimodal Imaging with Histochemical and Ultrastructural Analysis.International journal of molecular sciences · 2026Review
- "Bridging the clinical, molecular and genetic perspectives on myocarditis in post-COVID-19 era".International journal of cardiology. Cardiovascular risk and prevention · 2026Review
- Oxidative Stress in Takotsubo Syndrome: Insights into Extracellular Vesicles and Their Potential Clinical Relevance.Antioxidants (Basel, Switzerland) · 2026Review
- Critical Reappraisal of Takotsubo Syndrome (TS) and Myocarditis Association: "The Myocarditis-Like Features" Seen in TS Are Secondary Changes and not True Myocarditis.Reviews in cardiovascular medicine · 2026Review
- Immune Checkpoint Inhibitor-Associated Myocarditis: Risk, Diagnosis, and Clinical Impact.Journal of clinical medicine · 2026Review
- Longitudinal assessment of myocardial involvement in PASC-CVS: a single-center study from China based on multiparametric CMR.Frontiers in cardiovascular medicine · 2026Article
- Myocarditis in the Modern Era: Navigating Diagnosis, Innovative Treatments, the COVID-19 Challenge and the Role of Artificial Intelligence.Cardiology research and practice · 2026Review
- Diagnostic algorithm for clozapine-induced myocarditis: A systematic review.World journal of psychiatry · 2025Article
- Fulminant Myocarditis with VA-ECMO Support: Clinical Characteristics and Prognosis in a Cohort from a Tertiary Transplant Center.Biomedicines · 2025Article
- Novel Biomarkers and Advanced Imaging in Cardiovascular Risk Stratification for Rheumatic Diseases.Cureus · 2025Review
- Article
- Persistent somatostatin PET signs of inflammatory cells 4 to 5 months after acute myocarditis are linked to a poorer recovery of cardiac function.European journal of nuclear medicine and molecular imaging · 2025Article
- Sudden Cardiac Death in Pregnant Women-Literature Review and Autopsy Findings.Diagnostics (Basel, Switzerland) · 2025Review
- Prognostic value ofFrontiers in cardiovascular medicine · 2025Article
- Advances in the diagnosis of myocarditis in idiopathic inflammatory myopathies: an overview of diagnostic tests.Rheumatology (Oxford, England) · 2024Review
- Article
- Cardiovascular Events After Coronavirus Disease 2019 Vaccinations: Hypersensitivity Myocarditis After Coronavirus Disease 2019 Vaccines, Diagnostic and Long-term Considerations.Anatolian journal of cardiology · 2024Article
- Myocardial Strain for the Differentiation of Myocardial Involvement in the Post-Acute Sequelae of COVID-19-A Multiparametric Cardiac MRI Study.Tomography (Ann Arbor, Mich.) · 2024Article
- Myocarditis Related to the Use of Mesalazine.Journal of medical cases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endomyocardial biopsy as the cornerstone of diagnostics has been re-evaluated throughout the years, leaving unanswered questions on the precedence of it. The reported incidence of myocarditis has increased during the pandemic of coronavirus disease 2019 (COVID-19), reinforcing discussions on appropriate diagnostics of myocarditis. By analysis of evidence-based literature published within the last demi-decade, we aimed to summarize the most recent information in order to evaluate the current role of endomyocardial biopsy in diagnostics and management of myocarditis. For the most part, research published over the last five years showed ongoing uncertainty regarding the use, informativeness, safety and necessity of performing a biopsy. Special circumstances, such as fulminant clinical course or failure to respond to empirical treatment, were reconfirmed as justified indications, with a growing applicability of non-invasive diagnostic approaches for most other cases. We concluded that endomyocardial biopsy, if performed properly and with adjunct diagnostic methods, holds a critical role for treatment correction in specific histological subtypes of myocarditis and for differential diagnosis between immune-mediated myocarditis and secondary infections due to immunosuppressive treatment. A high level of possible misdiagnosing was detected, indicating the need to review terminology used to describe findings of myocardial inflammation that did not meet Dallas criteria.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.